The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGCP Infrastructure Investments Regulatory News (GCP)

Share Price Information for GCP Infrastructure Investments (GCP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 79.80
Bid: 77.80
Ask: 78.10
Change: 1.90 (2.44%)
Spread: 0.30 (0.386%)
Open: 79.80
High: 79.80
Low: 79.80
Prev. Close: 77.90
GCP Live PriceLast checked at -
GCP Infrastructure Investments is an Investment Trust

To provide shareholders with regular, sustainable, long-term dividend income and to preserve the capital value of its investments over the long term by generating exposure to infrastructure debt and/or similar assets.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GCP Applied Technologies Receives European Patent on Sustainable Cement Grinding Methods

18 Oct 2018 11:00



GCP Applied Technologies Receives European Patent on Sustainable Cement Grinding Methods

Bio-derived Solutions Enhance Efficiency of Cement Grinding and Reduce CO2 Emissions

CAMBRIDGE, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- GCP Applied Technologies Inc. (NYSE:GCP), a leading global provider of construction products technologies, is proud to announce the issuance of a patent for increasing the efficiency of cement grinding by using sustainable raw materials. The novel grinding aids and quality improvers allow the use of bio-derived glycerol and reduce the use and the impact of oil-derived chemicals.

This development continues GCP Applied Technologies’ commitment to offer cement producers a complete portfolio of products and services, enabling them to lead in cement quality, cost efficiency and sustainability. The new OPTEVA™ and TAVERO™ cement additives enable cement producers to reduce the energy consumption and the CO2 emissions associated with cement production, with a reduced use, or no use at all, of oil-derived chemicals.

“GCP Applied Technologies is focused on meeting the demands of modern cement plants,” said Dave Myers, vice president R&D and technical support. “We are committed to continuing research and development to improve cement additive products with innovative materials and services. GCP offers cement producers a complete portfolio of solutions that yield more sustainable cement production with enhanced quality and improved cost efficiency.”

European Patent No. EP 1 728 771 B1 has been granted and registered into seventeen European countries. The patent addresses methods for increasing the efficiency of cement and mineral grinding by using sustainable raw materials.

The patent relates to methods for improving the efficiency of grinding materials such as clinker and limestone, using glycerol derived from biofuel production, in combination with various grinding additives. GCP products can help shrink the carbon footprint of cement and concrete. Grinding aids and quality improvers make cement manufacturing more efficient, while concrete admixtures can reduce the amount of cement needed to achieve a given strength specification.

The company continues to expand its comprehensive portfolio of additives for cement production with high-performing quality improvers under the OPTEVA™ brand and innovative grinding aids under the TAVERO™ brand. 

Media RelationsPaul KeeffeT +1 617.498.4461mediainfo@gcpat.comInvestor RelationsJoseph DeCristofaroT +1 617.498.2616investors@gcpat.com

About GCP Applied Technologies

GCP is a leading global provider of construction products technologies that include additives for cement and concrete, the VERIFI® in-transit concrete management system, high-performance waterproofing products, and specialty systems. GCP products have been used to build some of the world’s most renowned structures. More information is available at www.gcpat.com.

This announcement contains “forward-looking statements,” that is, information related to future, not past, events. Such statements generally include the words “believes,” “plans,” “intends,” “targets,” “will,” “expects,” “suggests,” “anticipates,” “outlook,” “continues,” or similar expressions. Forward-looking statements include, without limitation, statements about expected financial positions; results of operations; cash flows; financing plans; business strategy; operating plans; capital and other expenditures; competitive positions; growth opportunities for existing products; benefits from new technology and cost reduction initiatives, plans and objectives; and markets for securities. Like other businesses, GCP is subject to risks and uncertainties that could cause its actual results to differ materially from its projections or that could cause other forward-looking statements to prove incorrect. Factors that could cause actual results to materially differ from those contained in the forward-looking statements, or that could cause other forward-looking statements to prove incorrect, include, without limitation, risks related to: the cyclical and seasonal nature of the industries that GCP serves; foreign operations, especially in emerging regions; changes in currency exchange rates; the cost and availability of raw materials and energy; the effectiveness of GCP’s research and development, new product introductions and growth investments; acquisitions and divestitures of assets and gains and losses from dispositions; developments affecting GCP’s outstanding liquidity and indebtedness, including debt covenants and interest rate exposure; developments affecting GCP’s funded and unfunded pension obligations; warranty and product liability claims; legal proceedings; the inability to establish or maintain certain business relationships and relationships with customers and suppliers or the inability to retain key personnel; and the handling of hazardous materials and the costs of compliance with environmental regulation. These and other factors are identified and described in more detail in GCP's Annual Report on Form 10-K, which has been filed with the U.S. Securities and Exchange Commission and is available online at www.sec.gov. Readers are cautioned not to place undue reliance on GCP’s projections and forward-looking statements, which speak only as the date thereof. GCP undertakes no obligation to publicly release any revision to the projections and forward-looking statements contained in this announcement, or to update them to reflect events or circumstances occurring after the date of this announcement.


Date   Source Headline
29th Apr 20222:33 pmRNSHolding(s) in Company
29th Apr 20227:00 amRNSInvestor Report at 31 March 2022
27th Apr 202211:47 amRNSDirector/PDMR Shareholding
26th Apr 20222:32 pmRNSHolding(s) in Company
25th Apr 20227:00 amRNSDirector/PDMR Shareholding
21st Apr 202211:26 amRNSDividend Declaration & Scrip Dividend Alternative
14th Apr 20224:12 pmRNSHolding(s) in Company
14th Apr 20227:00 amRNSNet Asset Value(s)
31st Mar 20227:00 amRNSTotal Voting Rights
8th Mar 20229:46 amRNSAdditional Listing and Total Voting Rights
24th Feb 20229:25 amRNSAdditional Listing
21st Feb 20227:00 amRNSDirector Declaration
14th Feb 20223:03 pmRNSResult of AGM
26th Jan 20221:26 pmRNSDirector/PDMR Shareholding
26th Jan 20221:24 pmRNSDirector/PDMR Shareholding
21st Jan 202212:10 pmRNSDividend Declaration & Scrip Dividend Alternative
21st Jan 20227:00 amRNSInvestor Report at 31 December 2021
18th Jan 20223:31 pmRNSUpdate research from QuotedData
17th Jan 20227:00 amRNSNet Asset Value(s)
10th Jan 20228:00 amRNSNotice of AGM
31st Dec 20217:00 amRNSTotal Voting Rights
16th Dec 20217:00 amRNSDirector Declaration
14th Dec 20217:00 amRNSAnnual report and financial statements
9th Dec 202110:39 amRNSDirector/PDMR Shareholding
9th Dec 20218:41 amRNSAdditional Listing and Total Voting Rights
1st Dec 20217:00 amRNSDirectorate Change
29th Nov 202110:09 amRNSAdditional Listing
11th Nov 20217:00 amRNSScrip Share Reference Price
29th Oct 20217:00 amRNSInvestor Report at 30 September 2021
28th Oct 20211:54 pmRNSDividend Declaration & Scrip Dividend Alternative
19th Oct 20217:00 amRNSNet Asset Value(s)
30th Sep 20217:00 amRNSTotal Voting Rights
17th Sep 20215:23 pmRNSNew Directorship Notification
9th Sep 202111:47 amRNSDirector/PDMR Shareholding
9th Sep 202111:47 amRNSAdditional Listing and Total Voting Rights
3rd Sep 20214:15 pmRNSNew Directorship Notification
27th Aug 202110:19 amRNSAdditional Listing
12th Aug 20217:00 amRNSScrip share reference price
9th Aug 202111:42 amRNSHolding(s) in Company
30th Jul 20217:00 amRNSInvestor Report at 30 June 2021 and RCF update
28th Jul 20217:00 amRNSDividend Declaration & Scrip Dividend Alternative
20th Jul 202110:59 amRNSUpdate research from QuotedData
16th Jul 20219:21 amRNSDirector/PDMR Shareholding
15th Jul 20217:00 amRNSNet Asset Value(s)
1st Jul 202110:55 amRNSHolding(s) in Company
30th Jun 20217:00 amRNSTotal Voting Rights
22nd Jun 202110:20 amRNSDirector/PDMR Shareholding
21st Jun 20211:21 pmRNSDirector/PDMR Shareholding
10th Jun 20217:00 amRNSHalf-yearly report and financial statements 2021
8th Jun 202112:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.